2025
Armbrust R, Fotopoulou C, Zocholl D, Chekerov R, Muallem MZ, Braicu I, Pietzner K, Harter P, Sehouli J.
Role of lymphadenectomy in advanced ovarian cancer – a subgroup analysis of the patients excluded from the LION trial (the Charité cohort).
Int J Gynecol Cancer. 2025 Feb 15:101683. doi: 10.1016/j.ijgc.2025.101683. Online ahead of print. PMID: 40057416
2024
Pfarr N, von Schwarzenberg K, Zocholl D, Merkelbach-Bruse S, Siemanowski J, Mayr EM, Herold S, Kleo K, Heukamp LC, Willing EM, Menzel M, Lehmann U, Bartels S, Chakraborty S, Baretton G, Demes MC, Döring C, Kazdal D, Budczies J, Rad R, Wild P, Christinat Y, McKee T, Schirmacher P, Horst D, Büttner R, Stenzinger A, Sehouli J, Vollbrecht C, Hummel M, Braicu EI, Weichert W; German HRD assay Harmonization Consortium.
High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency- Associated Genomic Instability in Ovarian Cancer.
JCO Precis Oncol. 2024 Mar;8:e2300348. doi: 10.1200/PO.23.00348.
Obermayr E, Mohr T, Schuster E, Braicu EI, Taube E, Sehouli J, Vergote I, Pujade-Lauraine E, Ray-Coquard I, Harter P, Wimberger P, Joly-Lobbedez F, Mahner S, Moll UM, Concin N, Zeillinger R.
Gene expression markers in peripheral blood and outcome in patients with platinum-resistant ovarian cancer: A study of the European GANNET53 consortium.
Int J Cancer. 2024 Apr 27. doi: 10.1002/ijc.34978. Epub ahead of print.
Fromhage G, Obermayr E, Bednarz-Knoll N, Van Gorp T, Welsch E, Polterauer S, Braicu EI, Mahner S, Sehouli J, Vergote I, Concin N, Kurtz S, Steinbiss S, Torge A, Zeillinger R, Wölber L, Brandt B.
Loss of copy numbers of retrotransposons (HERVK) on chromosome 7p11.2 impacts EGFR (Epidermal Growth Factor Receptor)-induced phenotypes for platinum sensitivity and long term survival in ovarian cancer-A study from the OVCAD consortium.
Int J Cancer. 2024 May 6. doi: 10.1002/ijc.34976. Epub ahead of print.
Arends CM, Kopp K, Hablesreiter R, Estrada N, Christen F, Moll UM, Zeillinger R, Schmitt WD, Sehouli J, Kulbe H, Fleischmann M, Ray-Coquard I, Zeimet A, Raspagliesi F, Zamagni C, Vergote I, Lorusso D, Concin N, Bullinger L, Braicu EI, Damm F.
Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer.
Leukemia. 2024 Jun;38(6):1378-1389. doi: 10.1038/s41375-024-02253-3. Epub 2024 Apr 18. Erratum in: Leukemia. 2024 Jun;38(6):1440. doi: 10.1038/s41375-024-02274-y.
2023
Glajzer J, Castillo-Tong DC, Richter R, Vergote I, Kulbe H, Vanderstichele A, Ruscito I, Trillsch F, Mustea A, Kreuzinger C, Gourley C, Gabra H, Taube ET, Dorigo O, Horst D, Keunecke C, Baum J, Angelotti T, Sehouli J, Braicu EI.
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ann Surg Oncol. 2023 Jan;30(1):35-45. doi: 10.1245/s10434-022-12459-3. Epub 2022 Sep 9
Kassuhn W, Cutillas PR, Kessler M, Sehouli J, Braicu EI, Blüthgen N, Kulbe H.
In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients.
Cancers (Basel). 2023 Jun 12;15(12):3155. doi: 10.3390/cancers15123155.
2022
Vanderstichele A, Busschaert P, Landolfo C, Olbrecht S, Coosemans A, Froyman W, Loverix L, Concin N, Braicu EI, Wimberger P, Van Nieuwenhuysen E, Han SN, Van Gorp T, Venken T, Heremans R, Neven P, Bourne T, Van Calster B, Timmerman D, Lambrechts D, Vergote I.
Nucleosome footprinting in plasma cell-free DNA for the pre-surgical diagnosis of ovarian cancer.
NPJ Genom Med. 2022 Apr 28;7(1):30.
Keunecke C, Kulbe H, Dreher F, Taube ET, Chekerov R, Horst D, Hummel M, Kessler T, Pietzner K, Kassuhn W, Heitz F, Muallem MZ, Lang SM, Vergote I, Dorigo O, Lammert H, du Bois A, Angelotti T, Fotopoulou C, Sehouli J, Braicu EI.
Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Gynecol Oncol. 2022 Jun 20:S0090-8258(22)00414-0
2021
Grabowski JP, Glajzer J, Richter R, Plett H, Muallem MZ, Braicu EI, Taube E, Sehouli J.
Lymphovascular space invasion and Ki67 as predictors of lymph node metastasis in primary low grade serous ovarian cancer.
Int J Gynecol Cancer. 2021 Jan;31(1):98-103. doi: 10.1136/ijgc-2020-001950.
Baum J, Braicu EI, Hunsicker O, Vergote I, Concin N, Van Nieuwenhuysen E, Feldheiser A, Achimas- Cadariu P, Darb-Esfahani S, Berger A, Fetica B, Mahner S, Papadia A, Wölber L, Gasparri ML, Vanderstichele A, Benedetti Panici P, Mueller MD, Ruscito I, Woopen H, Sehouli J.
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis.
Int J Gynecol Cancer. 2021 Feb 9:ijgc-2020-002023. doi: 10.1136/ijgc-2020-002023.
Kassuhn W, Klein O, Darb-Esfahani S, Lammert H, Handzik S, Taube ET, Schmitt WD, Keunecke C, Horst D, Dreher F, George J, Bowtell DD, Dorigo O, Hummel M, Sehouli J, Blüthgen N, Kulbe H, Braicu EI.
Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging.
Cancers (Basel). 2021 Mar 25;13(7):1512.
Salminen L, Braicu EI, Lääperi M, Jylhä A, Oksa S, Hietanen S, Sehouli J, Kulbe H, Bois AD, Mahner S, Harter P, Carpén O, Huhtinen K, Hynninen J, Hilvo M. A
Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer.
Cancers (Basel). 2021 Apr 7;13(8):1764.
Baum J, Braicu EI, Hunsicker O, Vergote I, Concin N, Van Nieuwenhuysen E, Feldheiser A, Achimas-Cadariu P, Darb-Esfahani S, Berger A, Fetica B, Mahner S, Papadia A, Wölber L, Gasparri ML, Vanderstichele A, Benedetti Panici P, Mueller MD, Ruscito I, Woopen H, Sehouli J.
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian
cancer: a multicenter analysis.
Int J Gynecol Cancer. 2021 May;31(5):713-720.
Woopen H, Rolf C, Braicu EI, Buttmann-Schweiger N, Barnes B, Baum J, Pietzner K, Kraywinkel K, Sehouli J.
Secondary malignancies in long-term ovarian cancer survivors: results of the ‚Carolin meets HANNA’study.
Int J Gynecol Cancer. 2021 May;31(5):709-712.
Obermayr E, Reiner A, Brandt B, Braicu EI, Reinthaller A, Loverix L, Concin N, Woelber L, Mahner S, Sehouli J, Vergote I, Zeillinger R.
The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium.
Cancers (Basel). 2021 May 26;13(11):2613.
2020
Hoffmann K, Berger H, Kulbe H, Thillainadarasan S, Mollenkopf HJ, Zemojtel T, Taube E, Darb-Esfahani S, Mangler M, Sehouli J, Chekerov R, Braicu EI, Meyer TF, Kessler M.
Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment.
EMBO J. 2020 Mar 16;39(6):e104013. doi: 10.15252/embj.2019104013. Epub 2020 Feb 3. PMID:
32009247; PMCID: PMC7073464.
Kulbe H, Klein O, Wu Z, Taube ET, Kassuhn W, Horst D, Darb-Esfahani S, Jank P, Abobaker S, Ringel F, du Bois A, Heitz F, Sehouli J, Braicu EI.
Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging.
Cancers (Basel). 2020 Jul 22;12(8):2000. doi: 10.3390/cancers12082000. PMID: 32707805; PMCID: PMC7463791.
2019
Guan J, Darb-Esfahani S, Richter R, Taube ET, Ruscito I, Mahner S, Woelber L, Prieske K, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI.
Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
J Cancer Res Clin Oncol. 2019 Apr;145(4):1063-1073. doi: 10.1007/s00432-019-02877-4.
Hunsicker O, Gericke S, Graw JA, Krannich A, Boemke W, Meyer O, Braicu I, Spies C, Sehouli J, Pruß A, Feldheiser A.
Transfusion of red blood cells does not impact progression-free and overall survival after surgery for ovarian cancer.
Transfusion. 2019 Dec;59(12):3589-3600.
2018
Ruscito I, Cacsire Castillo-Tong D, Vergote I, Ignat I, Stanske M, Vanderstichele A, Glajzer J, Kulbe H, Trillsch F, Mustea A, Kreuzinger C, Benedetti Panici P, Gourley C, Gabra H, Nuti M, Taube ET, Kessler M, Sehouli J, Darb-Esfahani S, Braicu EI.
Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
Br J Cancer. 2018 Jun 29. doi: 10.1038/s41416-018-0157-z.
Niemi RJ, Braicu EI, Kulbe H, Koistinen KM, Sehouli J, Puistola U, Mäenpää JU, Hilvo M.
Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid
metabolism.
Br J Cancer. 2018 Oct 8. doi: 10.1038/s41416-018-0270-z.
Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN.
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Br J Cancer. 2018 Oct;119(9):1060-1066. doi: 10.1038/s41416-018-0268-6.
Sehouli J, Braicu EI, Richter R, Denkert C, Jank P, Jurmeister PS, Kunze CA, Budczies J, Darb-Esfahani S, Schmitt WD, Traut A, Grabowski J, Taube E, Plett H.
Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the tumor bank ovarian cancer network.
Hum Pathol. 2018 Nov 11. pii: S0046-8177(18)30417-9. doi: 10.1016/j.humpath.2018.10.020.
2017
Biskup K, Braicu EI, Sehouli J, Tauber R, Blanchard V.
The ascites N-glycome of epithelial ovarian cancer patients.
J Proteomics. 2017 Mar 22;157:33-39. doi: 10.1016/j.jprot.2017.02.001.
2016
Gasimli K, Braicu EI, Nassir M, Richter R, Babayeva A, Chekerov R, Darb-Esfahani S, Sehouli J, Muallem MZ.
Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Ann Surg Oncol. 2016 Apr;23(4):1279-86.
Dimitrova D, Ruscito I, Olek S, Richter R, Hellwag A, Türbachova I, Woopen H, Baron U, Braicu EI, Sehouli J.
Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Tumour Biol. 2016 Jun 14.
Rohr I, Braicu EI, En-Nia A, Heinrich M, Richter R, Chekerov R, Dechend R, Heidecke H, Dragun D, Schäfer R, Gorny X, Lindquist JA, Brandt S, Sehouli J, Mertens PR.
Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC).
Cytokine. 2016 Sep;85:157-64.
Muallem MZ, Almuheimid J, Richter R, Braicu EI, Osman S, Sehouli J.
Diaphragmatic Surgery in Advanced Ovarian, Tubal and Peritoneal Cancer. A 7-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
Anticancer Res. 2016 Sep;36(9):4707-13.
2015
Gasimli K, Braicu EI, Richter R, Chekerov R, Sehouli J.
Prognostic and Predictive Value of the Peritoneal Cancer Index in Primary Advanced Epithelial Ovarian Cancer Patients After Complete Cytoreductive Surgery: Study of Tumor Bank Ovarian Cancer.
Ann Surg Oncol. 2015 Aug;22(8):2729-37.
2014
Pils D, Bachmayr-Heyda A, Auer K, Svoboda M, Auner V, Hager G, Obermayr E, Reiner A, Reinthaller A, Speiser P, Braicu I, Sehouli J, Lambrechts S, Vergote I, Mahner S, Berger A, Cacsire Castillo-Tong D, Zeillinger R.
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients – a study of the OVCAD consortium.
Eur J Cancer. 2014 Jan;50(1):99-110.
Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti- Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
Eur J Cancer. 2014 May 30.
2011
Fotopoulou C, Richter R, Braicu IE, Schmidt SC, Neuhaus P, Lichtenegger W, Sehouli J.
Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer.
Ann Surg Oncol. 2011 Jan;18(1):49–57.
Fotopoulou C, Richter R, Braicu EI, Kuhberg M, Feldheiser A, Schefold JC, Lichtenegger W, Sehouli J.
Impact of obesity on operative morbidity and clinical outcome in primary epithelial ovarian cancer after optimal primary tumor debulking.
Ann Surg Oncol. 2011 Mar 11.